에서 실시간으로 운영 중이에요! 자세히 알아보기

Myriad Genetics

MYGN

시가총액 US$3.81억

3.98 USD

-0.37

8.51%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

3.98

0.00

0%

1일

-8.51%

5일

-7.44%

1개월

3.11%

3개월

-35.7%

6개월

-20.4%

연초 이후

-35.18%

1년

-50.74%

5년

-87.61%

10년

-79.39%

소개: Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

직원 수: 2,700

건강관리 진단 및 리서치

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 4.8%

중립 85.7%

부정적 9.5%

Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026

SALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings conference call at 4:30 pm ET on Wednesday, November 4, 2026. The company's quarterly earnings will be released the same day after market close.

Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients.

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients.

Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial

SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, effective September 16, 2026.

Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial

This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse.

Piper Sandler cuts Myriad Genetics stock to Underweight, citing doubts about the genetic testing company's path to sustainable profitability.

This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse.

Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST. The presentation will be available through a live audio webcast link in the investor information section of Myriad's website at investor.myriad.com.

Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)---- $MYGN #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 30, 2026, Myriad Genetics reported that its second-quarter revenue declined 11% year-.

MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky

Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended adjusted EBITDA guidance. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors.

Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law.

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Myriad (MYGN) To Contact Him Directly To Discuss Their Options

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.